FLGT compared with AKBA: revenue, margins and what each company keeps, and the suppliers and customers both name

FLGTFulgent Genetics, Inc.

Mkt capRevenueRevenue

AKBAAkebia Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

FLGTFulgent Genetics, Inc.

AKBAAkebia Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

FLGT

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.1%▲+27.22%×1.69

Q2 FY26±12.9%▼−18.11%×1.40

Q1 FY26±17.8%▼−6.98%×0.39

Feb 27 '26±11.3%▼−38.09%×3.37

AKBA

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±33.6%▼−38.75%×1.15

Q2 FY26±35.9%▼−26.02%×0.72

= impliedFLGT realized, solidAKBA realized, hatchedOne scale, both sides: full bar = 39%× = |realized| ÷ impliedSource: market data

May 7 '26

±14.2%

▼−20.27%

×1.43

Q1 FY26±27.1%▲+9.09%×0.34

FLGTFulgent Genetics, Inc.

23.79▲+27.52%· post 23.79

Mkt cap$663.3MRevenue$90MQ3 FY26Revenue$323MFY25

AKBAAkebia Therapeutics, Inc.

0.40▼−6.02%· post 0.40

ClosedNov 6 '26

Mkt cap$111.4MRevenue$37MQ3 FY26Revenue$236MFY25

Compare

ClosedNov 6 '26

FLGTFulgent Genetics, Inc.

AKBAAkebia Therapeutics, Inc.

23.79▲+27.52%post 23.79

Price

0.40▼−6.02%post 0.40

$663.3M

Mkt cap

$111.4M

Q3 FY26$90M

Revenue

$37MQ3 FY26

FY25$323M

Revenue

$236MFY25

FLGT23.79▲+27.52%vsAKBA0.40▼−6.02%ClosedNov 6 '26